Natus Launches autoSCORE AI Globally — The First Deep-Learning Model to Deliver Expert-Level, Comprehensive Clinical EEG Interpretation at Scale
Trained on 30,000 expertly labelled EEG recordings and now FDA 510(k) cleared for routine, LTM, and Ambulatory EEG studies, autoSCORE™ goes beyond traditional spike and seizure detectors — delivering study-level assessments that can tell clinicians whether an EEG is normal or abnormal, with accuracy matching the world's top experts.
4 min read
Natus Medical Incorporated has announced the global launch of autoSCORE™, the first artificial intelligence model capable of delivering automatic and comprehensive clinical EEG interpretations with accuracy on par with medical experts. The announcement marks a major expansion of a tool that first entered the United States market in August 2024 for routine EEG studies — and now extends its reach to long-term monitoring (LTM) and ambulatory EEG studies, with regulatory clearance for both the US and international markets.
Developed in Norway by Holberg EEG and trained on 30,000 expertly labelled EEG recordings, autoSCORE is offered exclusively with Natus NeuroWorks software. It has received FDA 510(k) clearance for the expanded indication covering routine EEG, LTM, and Ambulatory EEG studies, and has also been awarded the CE mark for European and other international markets.
Why This Matters: The Resource Burden on Neurodiagnostics Teams
Visual EEG review remains the gold standard for identifying neurological abnormalities — but it is also one of the most resource-intensive tasks in clinical neurodiagnostics. Each study requires expert neurologist review, and the volume of EEG recordings generated by hospitals, epilepsy centres, and ambulatory monitoring programmes can place significant strain on department capacity and staff availability. The result is delays in reporting, pressure on clinical resources, and in some settings, constraints on patient access to timely neurodiagnostic care.
autoSCORE is designed to address this directly. By providing AI-generated study-level assessments that inform clinicians whether an EEG study is normal or abnormal — and by assessing multiple clinically relevant abnormalities rather than limiting detection to spikes and seizures alone — the tool enables neuro care teams to perform EEG analysis more efficiently and consistently, without displacing clinical expertise from the interpretive process.
"Developing the first AI model capable of interpreting clinical EEGs at the level of the world's top experts marks a defining moment for both Natus and the field of neurodiagnostics. Now, we're proud to bring this breakthrough innovation to healthcare providers globally — advancing our mission to expand patient access and deliver life-changing outcomes through cutting-edge neuro solutions."
— Chris Landon, CEO, Natus Neuro
Beyond Spike and Seizure Detection: What autoSCORE Does Differently
Traditional automated EEG tools have focused narrowly on detecting spikes and seizure activity — specific signal patterns that, while clinically important, represent only a subset of the abnormalities that neurologists assess during a full EEG review. autoSCORE takes a broader and more comprehensive approach, assessing multiple clinically relevant abnormalities and generating an overall study-level determination of normal or abnormal.
Early adopters particularly valued the platform's use of a closed AI model — an architecture that ensures consistency in outputs and maintains security standards, providing clinical teams with the confidence that the AI's assessments are reproducible and not subject to drift from external updates or unmonitored retraining. This design characteristic was cited as a key factor in clinical trust and adoption.
"Human teaming with intelligent machines has become a fundamental characteristic of a successful clinical decision support system. autoSCORE is a reliable colleague that can provide a second opinion — a powerful pathway to faster interventions."
— Dr. Ram Mohan Sankaraneni, Board-Certified Neurologist, Fellow of the American Epilepsy Society and the American Academy of Neurology
Regulatory Clearances and Global Availability
The global rollout of autoSCORE is supported by dual regulatory approvals. In the United States, the tool holds FDA 510(k) clearance for an expanded indication now covering routine EEG, long-term monitoring (LTM), and ambulatory EEG studies — extending well beyond its initial US clearance for routine studies alone. For European and other international markets, autoSCORE has received the CE mark, enabling its deployment across a broad range of healthcare systems globally.
The tool is available exclusively through Natus NeuroWorks software, integrating directly into the existing clinical workflow for neurophysiology departments rather than requiring separate platform adoption. This integration model positions autoSCORE as an enhancement to established neurodiagnostic infrastructure rather than a replacement, lowering the operational barrier to adoption for clinical teams already working within the Natus ecosystem.
Key Takeaways
- Natus Medical Incorporated has globally launched autoSCORE™ — the first AI model capable of comprehensive clinical EEG interpretation with accuracy matching medical experts, now available in the US and internationally across routine, LTM, and ambulatory EEG study types
- Developed by Holberg EEG in Norway, autoSCORE is built on a deep-learning model trained on 30,000 expertly labelled EEG recordings and is offered exclusively through Natus NeuroWorks software
- Unlike traditional automated detectors that flag only spikes and seizures, autoSCORE assesses multiple clinically relevant abnormalities and delivers study-level assessments — informing clinicians whether a study is normal or abnormal in the same way an expert neurologist would
- The tool uses a closed AI model architecture, ensuring consistency and security in clinical outputs — a key factor in early adopter confidence and trust in the platform as a genuine clinical decision support tool
- autoSCORE holds FDA 510(k) clearance for its expanded indication (routine, LTM, and ambulatory EEG) and CE mark for European and international markets, with the goal of expanding patient access to timely neurodiagnostic care globally